{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T18:10:17Z","timestamp":1793815817946,"version":"4.6.1"},"reference-count":46,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T00:00:00Z","timestamp":1762905600000},"content-version":"vor","delay-in-days":1034,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2023,1,13]],"date-time":"2023-01-13T00:00:00Z","timestamp":1673568000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100012774","name":"Innovation Fund Denmark","doi-asserted-by":"publisher","award":["6153-00002A"],"award-info":[{"award-number":["6153-00002A"]}],"id":[{"id":"10.13039\/100012774","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007460","name":"Arvid Nilssons Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007460","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008276","name":"Skibsreder Per Henriksen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008276","id-type":"DOI","asserted-by":"publisher"}]},{"name":"R & Hustrus Foundation"},{"DOI":"10.13039\/501100003035","name":"Aase and Ejnar Danielsens Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003035","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012774","name":"Innovationsfonden","doi-asserted-by":"publisher","award":["6153\u201000002A"],"award-info":[{"award-number":["6153\u201000002A"]}],"id":[{"id":"10.13039\/100012774","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007460","name":"Arvid Nilssons Fond","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007460","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008276","name":"Skibsreder Per Henriksen, R. og hustrus fond","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008276","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003035","name":"Aase og Ejnar Danielsens Fond","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003035","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Patients suffering from chronic ischaemic heart failure with reduced left ventricular ejection fraction (HFrEF) have reduced quality-of-life, repetitive hospital admissions, and reduced life expectancy. Allogeneic cell therapy is currently investigated as a potential treatment option after initially encouraging results from clinical autologous and allogeneic trials in patients with HFrEF. We aimed to investigate the allogeneic Cardiology Stem Cell Centre Adipose tissue derived mesenchymal Stromal Cell product (CSCC_ASC) as an add-on therapy in patients with chronic HFrEF.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>This is a Danish multi-centre double-blinded placebo-controlled phase II study with direct intra-myocardial injections of allogeneic CSCC_ASC. A total of 81 HFrEF patients were included and randomized 2:1 to CSCC_ASC or placebo injections. The inclusion criteria were reduced left ventricular ejection fraction (LVEF \u2264 45%), New York Heart Association (NYHA) class II-III despite optimal anti-congestive heart failure medication and no further revascularization options. Injections of 0.3 mL CSCC_ASC (total cell dose 100 \u00d7 106 ASCs) (n = 54) or isotonic saline (n = 27) were performed into the viable myocardium in the border zone of infarcted tissue using the NOGA Myostar\u00ae catheter (Biological Delivery System, Cordis, Johnson &amp; Johnson, USA). The primary endpoint, left ventricular end systolic volume (LVESV), was evaluated at 6-month follow-up. The safety was measured during a 3-years follow-up period.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Mean age was 67.0 \u00b1 9.0 years and 66.6 \u00b1 8.1 years in the ASC and placebo groups, respectively. LVESV was unchanged from baseline to 6-month follow-up in the ASC (125.7 \u00b1 68.8 mL and 126.3 \u00b1 72.5 mL, P = 0.827) and placebo (134.6 \u00b1 45.8 mL and 135.3 \u00b1 49.6 mL, P = 0.855) group without any differences between the groups (0.0 mL (95% CI \u22129.1 to 9.0 mL, P = 0.992). Neither were there significant changes in left ventricular end diastolic volume or LVEF within the two groups or between groups \u22125.7 mL (95% CI \u221216.7 to 5.3 mL, P = 0.306) and \u22121.7% (95% CI \u22124.4. to 1.0, P = 0.212), respectively). NYHA classification and 6-min walk test did not alter significantly in the two groups (P &amp;gt; 0.05). The quality-of-life, total symptom, and overall summary score improved significantly only in the ASC group but not between groups.<\/jats:p>\n                    <jats:p>There were 24 serious adverse events (SAEs) in the ASC group and 11 SAEs in the placebo group without any significant differences between the two groups at 1-year follow-up. Kaplan\u2013Meier plot using log-rank test of combined cardiac events showed an overall mean time to event of 30 \u00b1 2 months in the ASC group and 29 \u00b1 2 months in the placebo group without any differences between the groups during the 3 years follow-up period (P = 0.994).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Intramyocardial CSCC_ASC injections in patients with chronic HFrEF were safe but did not improve myocardial function or structure, nor clinical symptoms.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ehf2.14281","type":"journal-article","created":{"date-parts":[[2023,1,13]],"date-time":"2023-01-13T19:21:45Z","timestamp":1673637705000},"page":"1170-1183","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":54,"title":["Danish Phase II Trial Using Adipose Tissue Derived Mesenchymal Stromal Cells for Patients with Ischaemic Heart Failure"],"prefix":"10.1093","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1620-0002","authenticated-orcid":false,"given":"Abbas Ali","family":"Qayyum","sequence":"first","affiliation":[{"name":"Department of Cardiology and Cardiology Stem Cell Centre, The Heart Centre, Rigshospitalet, University of Copenhagen , Copenhagen ,","place":["Denmark"]},{"name":"Department of Cardiology, Hvidovre Hospital, University of Copenhagen , Copenhagen ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mette","family":"Mouridsen","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Herlev and Gentofte Hospital, University of Copenhagen , Copenhagen ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Nilsson","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Hvidovre Hospital, University of Copenhagen , Copenhagen ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ida","family":"Gustafsson","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Bispebjerg Hospital, University of Copenhagen , Copenhagen ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morten","family":"Schou","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Herlev and Gentofte Hospital, University of Copenhagen , Copenhagen ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olav Wendelboe","family":"Nielsen","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Bispebjerg Hospital, University of Copenhagen , Copenhagen ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens Dahlgaard","family":"Hove","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Hvidovre Hospital, University of Copenhagen , Copenhagen ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders Bruun","family":"Mathiasen","sequence":"additional","affiliation":[{"name":"Department of Cardiology and Cardiology Stem Cell Centre, The Heart Centre, Rigshospitalet, University of Copenhagen , Copenhagen ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"J\u00f8rgensen","sequence":"additional","affiliation":[{"name":"Department of Cardiology and Cardiology Stem Cell Centre, The Heart Centre, Rigshospitalet, University of Copenhagen , Copenhagen ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steffen","family":"Helqvist","sequence":"additional","affiliation":[{"name":"Department of Cardiology and Cardiology Stem Cell Centre, The Heart Centre, Rigshospitalet, University of Copenhagen , Copenhagen ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis Richard","family":"Joshi","sequence":"additional","affiliation":[{"name":"Department of Cardiology and Cardiology Stem Cell Centre, The Heart Centre, Rigshospitalet, University of Copenhagen , Copenhagen ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen M\u00f8nsted","family":"Johansen","sequence":"additional","affiliation":[{"name":"Department of Cardiology and Cardiology Stem Cell Centre, The Heart Centre, Rigshospitalet, University of Copenhagen , Copenhagen ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bjarke","family":"Follin","sequence":"additional","affiliation":[{"name":"Department of Cardiology and Cardiology Stem Cell Centre, The Heart Centre, Rigshospitalet, University of Copenhagen , Copenhagen ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morten","family":"Juhl","sequence":"additional","affiliation":[{"name":"Department of Cardiology and Cardiology Stem Cell Centre, The Heart Centre, Rigshospitalet, University of Copenhagen , Copenhagen ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisbeth Drozd","family":"H\u00f8jgaard","sequence":"additional","affiliation":[{"name":"Department of Cardiology and Cardiology Stem Cell Centre, The Heart Centre, Rigshospitalet, University of Copenhagen , Copenhagen ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mandana","family":"Haack-S\u00f8rensen","sequence":"additional","affiliation":[{"name":"Department of Cardiology and Cardiology Stem Cell Centre, The Heart Centre, Rigshospitalet, University of Copenhagen , Copenhagen ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annette","family":"Ekblond","sequence":"additional","affiliation":[{"name":"Department of Cardiology and Cardiology Stem Cell Centre, The Heart Centre, Rigshospitalet, University of Copenhagen , Copenhagen ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Kastrup","sequence":"additional","affiliation":[{"name":"Department of Cardiology and Cardiology Stem Cell Centre, The Heart Centre, Rigshospitalet, University of Copenhagen , Copenhagen ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,1,13]]},"reference":[{"key":"2026012114111969600_ehf214281-bib-0001","doi-asserted-by":"crossref","first-page":"e153","DOI":"10.1161\/CIR.0000000000001052","article-title":"Heart disease and stroke Statistics-2022 update: a report from the American Heart Association","volume":"145","author":"Tsao","year":"2022","journal-title":"Circulation"},{"key":"2026012114111969600_ehf214281-bib-0002","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1093\/eurheartj\/ehx248","article-title":"Global position paper on cardiovascular regenerative medicine","volume":"38","author":"Fern\u00e1ndez-Avil\u00e9s","year":"2017","journal-title":"Eur Heart J"},{"key":"2026012114111969600_ehf214281-bib-0003","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1093\/cvr\/cvaa337","article-title":"Insights into therapeutic products, preclinical research models, and clinical trials in cardiac regenerative and reparative medicine: where are we now and the way ahead. Current opinion paper of the ESC working group on cardiovascular regenerative and reparative medicine","volume":"117","author":"Grigorian-Shamagian","year":"2021","journal-title":"Cardiovasc Res"},{"key":"2026012114111969600_ehf214281-bib-0004","first-page":"608","article-title":"Mesenchymal stem cell therapy for patients with ischemic heart failure- past, present, and future","volume":"16","author":"Liang","year":"2021","journal-title":"Curr Stem Cell Res Ther"},{"key":"2026012114111969600_ehf214281-bib-0005","doi-asserted-by":"crossref","first-page":"354","DOI":"10.2174\/1574888X15999200820171432","article-title":"A systematic review and meta-analysis: safety and efficacy of mesenchymal stem cells therapy for heart failure","volume":"16","author":"Shen","year":"2021","journal-title":"Curr Stem Cell Res Ther"},{"key":"2026012114111969600_ehf214281-bib-0006","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.yjmcc.2014.06.016","article-title":"Cell therapy for human ischemic heart diseases: critical review and summary of the clinical experiences","volume":"75","author":"Pavo","year":"2014","journal-title":"J Mol Cell Cardiol"},{"key":"2026012114111969600_ehf214281-bib-0007","doi-asserted-by":"crossref","first-page":"2607","DOI":"10.1159\/000492704","article-title":"Stem cell therapy in heart diseases - cell types, mechanisms and improvement strategies","volume":"48","author":"M\u00fcller","year":"2018","journal-title":"Cell Physiol Biochem"},{"key":"2026012114111969600_ehf214281-bib-0008","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1093\/bmb\/ldw059","article-title":"Stem cell therapy for ischemic heart diseases","volume":"121","author":"Yu","year":"2017","journal-title":"Br Med Bull"},{"key":"2026012114111969600_ehf214281-bib-0009","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1161\/CIRCRESAHA.108.176826","article-title":"Paracrine mechanisms in adult stem cell signaling and therapy","volume":"103","author":"Gnecchi","year":"2008","journal-title":"Circ Res"},{"key":"2026012114111969600_ehf214281-bib-0010","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1161\/CIRCRESAHA.110.222703","article-title":"Bone marrow mesenchymal stem cells stimulate cardiac stem cell proliferation and differentiation","volume":"107","author":"Hatzistergos","year":"2010","journal-title":"Circ Res"},{"key":"2026012114111969600_ehf214281-bib-0011","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.yjmcc.2011.06.004","article-title":"Mesenchymal stromal cells affect cardiomyocyte growth through juxtacrine Notch-1\/Jagged-1 signaling and paracrine mechanisms: clues for cardiac regeneration","volume":"51","author":"Sassoli","year":"2011","journal-title":"J Mol Cell Cardiol"},{"key":"2026012114111969600_ehf214281-bib-0012","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.scr.2011.01.001","article-title":"Human mesenchymal stem cell-conditioned medium improves cardiac function following myocardial infarction","volume":"6","author":"Timmers","year":"2011","journal-title":"Stem Cell Res"},{"key":"2026012114111969600_ehf214281-bib-0013","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1186\/s12967-020-02504-8","article-title":"Mesenchymal stem cell mediates cardiac repair through autocrine, paracrine and endocrine axes","volume":"18","author":"Sid-Otmane","year":"2020","journal-title":"J Transl Med"},{"key":"2026012114111969600_ehf214281-bib-0014","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1016\/j.ymthe.2018.05.009","article-title":"Mesenchymal stem cell-based therapy for cardiovascular disease: Progress and challenges","volume":"26","author":"Bagno","year":"2018","journal-title":"Mol Ther"},{"key":"2026012114111969600_ehf214281-bib-0015","doi-asserted-by":"crossref","first-page":"161","DOI":"10.3109\/14017431.2011.569571","article-title":"Mesenchymal stromal cell derived endothelial progenitor treatment in patients with refractory angina","volume":"45","author":"Friis","year":"2011","journal-title":"Scand Cardiovasc J"},{"key":"2026012114111969600_ehf214281-bib-0016","doi-asserted-by":"crossref","first-page":"521","DOI":"10.3727\/096368912X636830","article-title":"Direct intramyocardial mesenchymal stromal cell injections in patients with severe refractory angina: one-year follow-up","volume":"22","author":"Haack-S\u00f8rensen","year":"2013","journal-title":"Cell Transplant"},{"key":"2026012114111969600_ehf214281-bib-0017","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.ijcard.2013.10.079","article-title":"Autotransplantation of mesenchymal stromal cells from bone-marrow to heart in patients with severe stable coronary artery disease and refractory angina-final 3-year follow-up","volume":"170","author":"Mathiasen","year":"2013","journal-title":"Int J Cardiol"},{"key":"2026012114111969600_ehf214281-bib-0018","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1093\/eurheartj\/ehv136","article-title":"Bone marrow-derived mesenchymal stromal cell treatment in patients with severe ischaemic heart failure: a randomized placebo-controlled trial (MSC-HF trial)","volume":"36","author":"Mathiasen","year":"2015","journal-title":"Eur Heart J"},{"key":"2026012114111969600_ehf214281-bib-0019","doi-asserted-by":"crossref","first-page":"421","DOI":"10.2217\/rme.12.17","article-title":"Adipose-derived mesenchymal stromal cells for chronic myocardial ischemia (MyStromalCell trial): study design","volume":"7","author":"Qayyum","year":"2012","journal-title":"Regen Med"},{"key":"2026012114111969600_ehf214281-bib-0020","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1161\/CIRCRESAHA.118.312823","article-title":"Safety and efficacy of intracoronary infusion of allogeneic human cardiac stem cells in patients with ST-segment elevation myocardial infarction and left ventricular dysfunction","volume":"123","author":"Fern\u00e1ndez-Avil\u00e9s","year":"2018","journal-title":"Circ Res"},{"key":"2026012114111969600_ehf214281-bib-0021","doi-asserted-by":"crossref","DOI":"10.1155\/2017\/5237063","article-title":"Adipose-derived stromal cells for treatment of patients with chronic ischemic heart disease (MyStromalCell trial): a randomized placebo-controlled study","volume":"2017","author":"Qayyum","year":"2017","journal-title":"Stem Cells Int"},{"key":"2026012114111969600_ehf214281-bib-0022","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1186\/s12967-019-2110-1","article-title":"Autologous adipose-derived stromal cell treatment for patients with refractory angina (MyStromalCell trial): 3-years follow-up results","volume":"17","author":"Qayyum","year":"2019","journal-title":"J Transl Med"},{"key":"2026012114111969600_ehf214281-bib-0023","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1002\/sctm.17-0040","article-title":"Cryopreserved off-the-shelf allogeneic adipose-derived stromal cells for therapy in patients with ischemic heart disease and heart failure-a safety study","volume":"6","author":"Kastrup","year":"2017","journal-title":"Stem Cells Transl Med"},{"key":"2026012114111969600_ehf214281-bib-0024","doi-asserted-by":"crossref","DOI":"10.1155\/2017\/8506370","article-title":"Rationale and Design of the First Double-Blind, placebo-controlled trial with allogeneic adipose tissue-derived stromal cell therapy in patients with ischemic heart failure: a phase II Danish multicentre study","volume":"2017","author":"Kastrup","year":"2017","journal-title":"Stem Cells International"},{"key":"2026012114111969600_ehf214281-bib-0025","doi-asserted-by":"crossref","first-page":"93","DOI":"10.3109\/00365513.2015.1099723","article-title":"Comparison of clinical grade human platelet lysates for cultivation of mesenchymal stromal cells from bone marrow and adipose tissue","volume":"76","author":"Juhl","year":"2016","journal-title":"Scand J Clin Lab Invest"},{"key":"2026012114111969600_ehf214281-bib-0026","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1186\/s12967-016-1080-9","article-title":"Culture expansion of adipose derived stromal cells. A closed automated quantum cell expansion system compared with manual flask-based culture","volume":"14","author":"Haack-S\u00f8rensen","year":"2016","journal-title":"J Transl Med"},{"key":"2026012114111969600_ehf214281-bib-0027","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1186\/1479-5876-11-219","article-title":"Identical effects of VEGF and serum-deprivation on phenotype and function of adipose-derived stromal cells from healthy donors and patients with ischemic heart disease","volume":"11","author":"Follin","year":"2013","journal-title":"J Transl Med"},{"key":"2026012114111969600_ehf214281-bib-0028","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1080\/00365513.2018.1462082","article-title":"Development of large-scale manufacturing of adipose-derived stromal cells for clinical applications using bioreactors and human platelet lysate","volume":"78","author":"Haack-S\u00f8rensen","year":"2018","journal-title":"Scand J Clin Lab Invest"},{"key":"2026012114111969600_ehf214281-bib-0029","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/4664917","article-title":"GMP Compliant Production of a Cryopreserved Adipose-Derived Stromal Cell Product for Feasible and Allogeneic Clinical Use","volume":"2022","author":"Haack-S\u00f8rensen","year":"2022","journal-title":"Stem Cells Int"},{"key":"2026012114111969600_ehf214281-bib-0030","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1080\/00365513.2017.1354258","article-title":"Influence of patient related factors on number of mesenchymal stromal cells reached after in vitro culture expansion for clinical treatment","volume":"77","author":"Qayyum","year":"2017","journal-title":"Scand J Clin Lab Invest"},{"key":"2026012114111969600_ehf214281-bib-0031","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2021.709795","article-title":"Son of a lesser god: the case of cell therapy for refractory angina","volume":"8","author":"Bassetti","year":"2021","journal-title":"Front Cardiovasc Med"},{"key":"2026012114111969600_ehf214281-bib-0032","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1186\/s13287-015-0143-9","article-title":"Endpoints in stem cell trials in ischemic heart failure","volume":"6","author":"Banovic","year":"2015","journal-title":"Stem Cell Res Ther"},{"key":"2026012114111969600_ehf214281-bib-0033","article-title":"The current dilemma and breakthrough of stem cell therapy in ischemic heart disease","volume":"9","author":"Liu","year":"2021","journal-title":"Front Cell Dev Biol"},{"key":"2026012114111969600_ehf214281-bib-0034","first-page":"16","article-title":"The sad plight of cell therapy for heart failure: causes and consequences","volume":"2","author":"Bolli","year":"2022","journal-title":"J Cardiovasc Aging"},{"key":"2026012114111969600_ehf214281-bib-0035","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/s41536-019-0083-6","article-title":"Mesenchymal stem cell perspective: cell biology to clinical progress","volume":"4","author":"Pittenger","year":"2019","journal-title":"NPJ Regen Med"},{"key":"2026012114111969600_ehf214281-bib-0036","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1161\/CIRCRESAHA.116.302317","article-title":"Innate immunity and the failing heart: the cytokine hypothesis revisited","volume":"116","author":"Mann","year":"2015","journal-title":"Circ Res"},{"key":"2026012114111969600_ehf214281-bib-0037","doi-asserted-by":"crossref","first-page":"11758","DOI":"10.3390\/ijms222111758","article-title":"The initial cardiac tissue response to cryopreserved allogeneic adipose tissue-derived mesenchymal stromal cells in rats with chronic ischemic cardiomyopathy","volume":"22","author":"Follin","year":"2021","journal-title":"Int J Mol Sci"},{"key":"2026012114111969600_ehf214281-bib-0038","volume-title":"Trial of Cell Therapy for HF Misses Primary Endpoint, but Signals a Path Forward","year":"2022"},{"key":"2026012114111969600_ehf214281-bib-0039","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1016\/j.mayocp.2020.02.031","article-title":"Larger end-diastolic volume associates with response to cell therapy in patients with nonischemic dilated cardiomyopathy","volume":"95","author":"Frljak","year":"2020","journal-title":"Mayo Clin Proc"},{"key":"2026012114111969600_ehf214281-bib-0040","doi-asserted-by":"crossref","first-page":"3345","DOI":"10.1002\/ehf2.13031","article-title":"Cardiopoietic stem cell therapy in ischaemic heart failure: long-term clinical outcomes","volume":"7","author":"Bartunek","year":"2020","journal-title":"ESC Heart Fail"},{"key":"2026012114111969600_ehf214281-bib-0041","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1161\/CIRCRESAHA.119.314951","article-title":"Phase 3 DREAM-HF trial of mesenchymal precursor cells in chronic heart failure","volume":"125","author":"Borow","year":"2019","journal-title":"Circ Res"},{"key":"2026012114111969600_ehf214281-bib-0042","doi-asserted-by":"crossref","first-page":"3451","DOI":"10.1093\/eurheartj\/ehaa541","article-title":"Intracoronary ALLogeneic heart STem cells to achieve myocardial regeneration (ALLSTAR): a randomized, placebo-controlled, double-blinded trial","volume":"41","author":"Makkar","year":"2020","journal-title":"Eur Heart J"},{"key":"2026012114111969600_ehf214281-bib-0043","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1080\/14712598.2022.2016695","article-title":"Mechanism of action of mesenchymal stem cells (MSCs): impact of delivery method","volume":"22","author":"Bagno","year":"2022","journal-title":"Expert Opin Biol Ther"},{"key":"2026012114111969600_ehf214281-bib-0044","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2022.833335","article-title":"Targeted delivery for cardiac regeneration: comparison of intra-coronary infusion and intra-myocardial injection in porcine hearts","volume":"9","author":"Vekstein","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"2026012114111969600_ehf214281-bib-0045","first-page":"184","article-title":"Intramyocardial stem cell injection: go (ne) with the flow","volume":"38","author":"van den Akker","year":"2017","journal-title":"Eur Heart J"},{"key":"2026012114111969600_ehf214281-bib-0046","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.yjmcc.2010.08.005","article-title":"Paracrine mechanisms of stem cell reparative and regenerative actions in the heart","volume":"50","author":"Mirotsou","year":"2011","journal-title":"J Mol Cell Cardiol"}],"container-title":["ESC Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ehf2.14281","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/ehf2.14281","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/10\/2\/1170\/65051375\/eschf_10_2_1170.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/10\/2\/1170\/65051375\/eschf_10_2_1170.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T19:12:39Z","timestamp":1769022759000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eschf\/article\/10\/2\/1170\/8304878"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,13]]},"references-count":46,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,1,13]]},"published-print":{"date-parts":[[2023,4,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ehf2.14281","relation":{},"ISSN":["2055-5822"],"issn-type":[{"value":"2055-5822","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,4]]},"published":{"date-parts":[[2023,1,13]]},"assertion":[{"value":"2022-09-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-12-15","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-01-13","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}